NNIT A/S

12/2020 NNIT acquires Excellis Health Solutions - Seite 2

Strategic rationale
The combination of pharma production IT winning solutions and Excellis’ supply chain expertise strengthens NNIT’s international deliveries and helps secure new manufacturing execution systems (MES) implementation and TraceLink integration projects.
Additionally, NNIT can integrate information from manufacturing processes with information from the supply chain, providing clients with an increased overview and control over the supply chain.
Excellis’ unique position as the only global reselling and implementation partner of TraceLink will facilitate positioning of cloud MES, making NNIT a key service provider for production and supply chain cloud solutions.

Further, NNIT and Excellis can collaborate to offer end-to-end MS Dynamics and SAP S/4 Hana services, from vendor selection and advisory to implementation and application outsourcing as well as supporting Excellis’s customers in adapting the wide range of Veeva Solutions offerings.

About Excellis
Headquartered in New Hope, Pennsylvania in the US. Excellis provide end-to-end supply chain consulting services on a global basis for the life sciences industry. The company employs 100+ staff and independent contractors, mainly located in its headquarter and the company’s Manchester, UK office.

For the financial year 2020, Excellis is expected to generate revenue of around DKK 110 million and normalized operating profit of around DKK 19 million equal to an operating profit margin of around 17%. In 2021 revenue is expected to grow 15-20% with an operating profit margin at the same level as in 2020.

Outlook
The acquisition is expected to generate additional revenue in the last two months of 2020 of around DKK 16 million corresponding to approximately 0.5pp growth in 2020.
As a result, the outlook for 2020 in constant currencies is increased:

• Revenue growth around -7.5% in constant currencies, while expected growth excluding Excellis is maintained at around -8% in constant currencies
• Operating profit margin before special items of around 6% in constant currencies is maintained
• Level of investment (CAPEX) is 5-7% of total revenue is maintained excluding the acquisition of Excellis

Contacts for further information

Investor relations:                     Media relations: